BioCorRx Inc (OTC: BICX) is a pharmaceutical and addiction treatment company focused on developing and commercializing products for substance use disorders. Revenue derives from a combination of grant income and product sales, with grant income of $2,435,848 recognized in FY2025 compared to $1,473,276 in FY2024, representing the dominant income source disclosed in the 10-K filed March 31, 2026. In March 2025, subsidiary BioCorRx Pharmaceuticals Inc. acquired Lucemyra, an FDA-approved prescription medication for opioid withdrawal, from US WorldMeds via an asset purchase agreement with a $400,000 upfront purchase price structured as a 50% net sales revenue share. The company also holds a $11,029,977 National Institutes of Health grant awarded March 1, 2024, funding research on BICX104, a sustained-release naltrexone implant targeting methamphetamine use disorder. Two officers and directors together with five non-employee directors controlled approximately 66.50% of outstanding voting equity as of the FY2025 filing. The company carries accumulated deficit and has funded operations substantially through equity issuances and grants.

Revenue model

Grant income from NIH/NIDA awards, product net sales from Lucemyra (opioid withdrawal medication acquired March 2025 via asset purchase), and equity raises including common stock and warrant issuances to accredited investors.

Products and services

Lucemyra: FDA-approved prescription medication for opioid withdrawal, acquired from US WorldMeds in March 2025. BICX104: sustained-release naltrexone implant in research stage targeting methamphetamine use disorder, funded by a $11,029,977 NIH NIDA grant awarded March 1, 2024.

Customers and end markets

End markets are addiction treatment, specifically opioid use disorder and methamphetamine use disorder. Grant funding source is the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health.

Value-chain role

Drug developer and commercializer in addiction treatment. Conducts pharmaceutical R&D via grant-funded clinical programs and holds commercial product rights to an acquired FDA-approved drug. Uses a sales representative agreement structure for commercialization.

Geographic exposure

United States. No international operations are disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-31

Industry: Services-Specialty Outpatient Facilities, NEC Peers: Regional Health Properties Inc AlerisLife Inc. Sonida Senior Living Inc HCA Healthcare Inc HQDA ELDERLY LIFE NETWORK CORP. IMAC Holdings Inc Joint Corp SUNLINK HEALTH SYSTEMS INC